ACERCA DE ESTE EPISODIO
Amiodarone monitoring: are existing guidelines outdated? In this interview, A. John Camm, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Tiffany Y. Hu, MD, discuss Amiodarone monitoring in 2021.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Inglés
Estados Unidos
TRANSCRIPCIÓN 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
BUSCAR EPISODIOS ANTERIORES
Buscar episodios anteriores de ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research.
OTROS EPISODIOS EN ESTE PODCAST
Randomized trials in stable ischemic heart disease (SIHD) show revascularization does not reduce death or myocardial infarction versus guideline-directed medical therapy, with benefit limited to symptom relief. This likely reflects lesion–ischemia mismatch, unclear ischemia origin, effective modern…
ecent advancements in echocardiography since ACC.25 highlight a shift toward greater precision, efficiency, and consistency in cardiac imaging. Standardized echo reporting is now recognized as a key marker of quality care, improving communication and supporting more reliable clinical decisions, whi…
The "Food is Medicine" approach is central to cardiovascular disease (CVD) prevention because diet directly shapes key risk factors, making nutrition a powerful, modifiable intervention. Medically tailored meals (MTMs) are fully prepared, condition-specific meals prescribed to meet the clinical nee…
Nonobstructive hypertrophic cardiomyopathy (HCM) represents one of the greatest areas of unmet need in HCM management. A key question is identifying the primary driver of symptoms in these patients, as many experience significant functional limitations despite the absence of left ventricular outflo…
The VESALIUS-CV trial demonstrated that the PCSK9 inhibitor evolocumab significantly reduced the risk of a first major cardiovascular event in patients with diabetes who had no known significant atherosclerosis. These findings challenge current clinical practice, where PCSK9 inhibitors are typicall…
Descargo de responsabilidad: El podcast y el arte incluidos en esta página son de American College of Cardiology, que es propiedad de su propietario y no está afiliado ni respaldado por Listen Notes, Inc.
EDITAR
Gracias por ayudar a mantener actualizada la base de datos de podcasts.
